2024 - Psychedelic Therapy: Is the Future of Mental Healthcare Finally Here?

Psychedelic therapy is at a crossroads. It holds immense potential to be the transformative tool we urgently need to address the limitations of existing treatments, but if we take the wrong step, it could also become just another line in medicine’s long history of almost miracles. How should we proceed? What steps can you take to ensure the future of this promising field?
The roundtable will be hosted by Angela Terhune-Hargrove, MHA, an accomplished Senior Business Development and Clinical Research Professional at Elligo Health Research® with vast professional and close personal psychedelic research experience. It will feature Greg Mayes, a 2-time founder and pharmaceutical drug developer with 20 years of experience who currently serves as President and CEO of Antios Therapeutics. It will also feature Kathryn LaRoe-Higgs, a renowned psychedelic psychotherapist with over a decade’s experience supporting Special Operations veterans with complex post-traumatic stress disorder (C-PTSD) and post-traumatic stress disorder (PTSD).
Read more...
Join the Elligo Elite Learning Series roundtable for an open discussion on shaping the future of mental healthcare with psychedelic therapy research.
Keywords: FDA, Drug Discovery, FDA Guidance, Mental Health, Major Depressive Disorder, Psilocybin Therapy, Psychedelics, Psychedelic Drug, Basic Research, MDD, Mental Health Disorder